7CI5

Crystal structure of P.aeruginosa LpxC in complex with inhibitor

Summary for 7CI5

• Entry DOI: 10.2210/pdb7ci5/pdb
• Descriptor: UDP-3-O-acyl-N-acetylglucosamine deacetylase, (3R)-3-azanyl-4-oxidanylidene-4-[[3-(trifluoromethyloxy)phenyl]amino]butanoic acid, 3[N-MORPHOLINO]PROPANE SULFONIC ACID, ... (5 entities in total)
• Functional Keywords: udp-3-o-acyl-n-acetylglucosamine deacetylase, enva, lpxc, pseudomonas aeruginosa, hydrolase
• Biological source: Pseudomonas aeruginosa PAO1
• Total number of polymer chains: 4
• Total formula weight: 134854.00

Authors

Mima, M.,Baker, L.M.,Surgenor, A.,Robertson, A. (deposition date: 2020-07-07, release date: 2020-12-02, Last modification date: 2023-11-29)

Primary citation

Yamada, Y.,Takashima, H.,Walmsley, D.L.,Ushiyama, F.,Matsuda, Y.,Kanazawa, H.,Yamaguchi-Sasaki, T.,Tanaka-Yamamoto, N.,Yamagishi, J.,Kurimoto-Tsuruta, R.,Ogata, Y.,Ohtake, N.,Angove, H.,Baker, L.,Harris, R.,Macias, A.,Robertson, A.,Surgenor, A.,Watanabe, H.,Nakano, K.,Mima, M.,Iwamoto, K.,Okada, A.,Takata, I.,Hitaka, K.,Tanaka, A.,Fujita, K.,Sugiyama, H.,Hubbard, R.E.
Fragment-Based Discovery of Novel Non-Hydroxamate LpxC Inhibitors with Antibacterial Activity.
J.Med.Chem., 63:14805-14820, 2020

PubMed Abstract: UDP-3--acyl--acetylglucosamine deacetylase (LpxC) is a zinc metalloenzyme that catalyzes the first committed step in the biosynthesis of Lipid A, an essential component of the cell envelope of Gram-negative bacteria. The most advanced, disclosed LpxC inhibitors showing antibacterial activity coordinate zinc through a hydroxamate moiety with concerns about binding to other metalloenzymes. Here, we describe the discovery, optimization, and efficacy of two series of compounds derived from fragments with differing modes of zinc chelation. A series was evolved from a fragment where a glycine moiety complexes zinc, which achieved low nanomolar potency in an enzyme functional assay but poor antibacterial activity on cell cultures. A second series was based on a fragment that chelated zinc through an imidazole moiety. Structure-guided design led to a 2-(1-hydroxyethyl)-imidazole derivative exhibiting low nanomolar inhibition of LpxC and a minimum inhibitory concentration (MIC) of 4 μg/mL against , which is little affected by the presence of albumin.

PubMed: 33210531
DOI: 10.1021/acs.jmedchem.0c01215

Experimental method

X-RAY DIFFRACTION (2.5 Å)